Department of Dermatology, PBM Hospital and SP Medical College, Bikaner, Rajasthan, India.
Br J Dermatol. 2013 May;168(5):1114-9. doi: 10.1111/bjd.12205.
BACKGROUND: Radiofrequency-induced heat therapy (RFHT) has been found to be safe and effective against cutaneous leishmaniasis (CL) in the short term, but its long-term efficacy is unclear. OBJECTIVES: To compare the long-term efficacy of RFHT vs. intralesional sodium stibogluconate (SSG) injections in the treatment of CL in India. METHODS: One hundred patients with a confirmed diagnosis of CL were randomly assigned in a 1 : 1 ratio to receive topical RFHT for 30-60 s or seven intralesional injections of SSG (50 mg cm(-2) of lesion). Improvement and recurrence were monitored every 15 days after the initiation of treatment for 4 months and then at 5, 6, 9, 12 and 18 months post-treatment; the rates of complete cure were compared. RESULTS: Lesions were healed in 47 out of 50 patients (94%) in the RFHT group and in 46 out of 50 patients (92%) in the SSG group at week 12. Time to complete healing was comparable in the two groups. At 6 months post-treatment, cure rates in the RFHT and SSG groups were 98% [95% confidence interval (CI) 94-100%] and 94% (95% CI 86-100%), respectively. Age, sex and lesion size or number had no effect on cure rates. No relapse of infection was recorded in cured patients in either group up to 12-18 months after initiation of treatment. Skin biopsies of cured lesions in eight out of eight (100%) patients from the RFHT group and three of three from the SSG group at 12 months showed minimal fibrosis and were negative for Leishmania tropica by polymerase chain reaction test. CONCLUSIONS: A single application of RFHT is safe, cosmetically acceptable and effective in inducing a long-term cure of CL.
背景:射频热疗(RFHT)已被证明在短期内治疗皮肤利什曼病(CL)是安全且有效的,但长期疗效尚不清楚。
目的:比较 RFHT 与病灶内注射葡萄糖酸锑钠(SSG)治疗印度 CL 的长期疗效。
方法:100 例确诊为 CL 的患者以 1:1 的比例随机分配,分别接受 30-60 秒的局部 RFHT 或 7 次病灶内注射 SSG(病变 50mg·cm(-2))。治疗开始后每 15 天监测一次,持续 4 个月,然后在治疗后 5、6、9、12 和 18 个月监测,比较完全治愈的比例。
结果:RFHT 组 50 例患者中有 47 例(94%)和 SSG 组 50 例患者中有 46 例(92%)在第 12 周时皮损痊愈。两组完全愈合时间相当。治疗后 6 个月,RFHT 组和 SSG 组的治愈率分别为 98%[95%可信区间(CI)94-100%]和 94%(95% CI 86-100%)。年龄、性别以及皮损大小或数量对治愈率均无影响。在开始治疗后 12-18 个月,两组治愈患者均未出现感染复发。RFHT 组 8 例患者中有 8 例(100%)和 SSG 组 3 例患者中有 3 例(100%)在 12 个月时进行皮损活检,发现最小纤维化,聚合酶链反应检测均为利什曼原虫阴性。
结论:单次 RFHT 应用是安全的、美观的、有效的,可长期治愈 CL。
J Eur Acad Dermatol Venereol. 2009-10
Vaccines (Basel). 2025-1-26
Indian J Crit Care Med. 2021-5
J Res Med Sci. 2021-2-27
Front Cell Infect Microbiol. 2021-3-17
Fac Rev. 2020-12-22